Elutia Receives $8M Escrow Payment From Boston Scientific Deal
Elutia has collected $8 million tied to its BioEnvelope sale, giving the company full funding through 2029.
Elutia has received an $8 million payment previously held in escrow, completing the financial settlement tied to the sale of its BioEnvelope business to Boston Scientific, the company announced Monday.
The full release of the escrowed funds marks the final financial milestone stemming from that divestiture, with the proceeds now bolstering Elutia's balance sheet through the end of 2029, according to the company.
Read more Aptera Cuts Production Capital Estimate by Nearly Half to $25M →
The funding runway to 2029 provides Elutia with an extended period of operational stability, reducing near-term capital-raising pressure as the company pursues its remaining business lines. Escrow arrangements of this type are standard in mergers and acquisitions, typically held to cover potential post-closing indemnification claims before being released to the seller once conditions are satisfied.
The BioEnvelope product line, which Elutia divested to Boston Scientific, represented a significant segment of the company's prior commercial portfolio. The completed payment signals that post-closing contingencies tied to that transaction have been resolved to both parties' satisfaction.
Continue reading at GlobeNewswire - Mergers And Acquisitions.
